XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer
Agreement Centers on XBiotech's Proprietary Manufacturing Technology to Advance Anti-NY-ESO-1 Antibody 12D7
AUSTIN, Texas, April 02, 2018 (GLOBE NEWSWIRE) -- XBiotech USA, Inc. (NASDAQ:XBIT) announced today that it has obtained an exclusive, worldwide license from CT Atlantic AG (CTA), a Swiss biotechnology company. Under the terms of the license agreement, XBiotech will use its proprietary manufacturing technology to advance the development of the True HumanTM anti-NY-ESO-1 monoclonal antibody, 12D7. Accordingly, XBiotech will now begin to establish the production capability to enable 12D7 clinical development.
The 12D7 antibody targets NY-ESO-1, a cancer-related protein commonly found in many kinds of aggressive tumors. The therapeutic use of 12D7 offers the potential to target advanced tumors by activating cellular immunity or antibody directed immune responses against tumors. A 12D7 therapy may be combined with other therapies that unleash the immune system to produce anti-cancer responses.
John Simard, President & CEO of XBiotech, commented, "The 12D7 antibody was isolated from a human immune response against cancer and is therefore a logical fit with our pipeline of human-derived antibodies. 12D7 offers the potential to be used as a therapy with minimal side effects-and safely in combinations with other agents, including checkpoint inhibitors-to help direct a patient's immune response against their cancer."
Simard further commented, "Although NY-ESO-1 has been the subject of an enormous amount of scientific investigation, pointing to its association with tumors and anti-tumor immunity, the 12D7 antibody has yet to be evaluated in clinical trials. 12D7 is a good example of how our unique manufacturing technology can be used to help advance promising candidates discovered elsewhere."
Prof. Alex Knuth, M.D., member of the Board of Directors at CTA, Medical Director and Chief Executive Officer of the National Center for Cancer Care and Research (NCCCR) and Chairman of Cancer Services at Hamad Medical Corporation, commented, "I am excited to bring this NY-ESO-1 specific True Human antibody to the clinic with the advanced technologies and expert guidance of XBiotech. NY-ESO-1 is the most immunogenic human cancer antigen known to date. The 12D7 antibody comes from a melanoma patient with a remarkably favourable disease course despite advanced metastasis. NY-ESO-1 immunity appears to predict a better response to immune checkpoint interventions and the 12D7 antibody has been shown to support conventional treatments like chemotherapy with better outcomes in animal models; and in combination with radiotherapy, 12D7 may also amplify immune responses against cancer cells."
About 12D7 Antibody
Work from the laboratories of Dr. Alexander Knuth and Dr. Steve Rosenberg previously showed that cellular immunity against NY-ESO-1 can be activated in cancer patients. The 12D7 antibody is expected to target the NY-ESO-1 antigen directly, as well as work to help direct the patient's cellular immune response against NY-ESO-1 bearing tumors. 12D7 is the first True Human monoclonal antibody targeting NY-ESO-1.
NY-ESO-1 was discovered by researchers at the Ludwig Institute for Cancer Research and Weill Medical College of Cornell University in New York. Interestingly, NY-ESO-1 is encoded by the sex-linked X chromosome and is deregulated and expressed in a number of forms of cancer. NY-ESO-1 function is still not fully understood but may be involved in cell division in cancer. Consequently, expression of NY-ESO-1 is found in a wide range of metastatic tumors, including about 33% of all cancers of the bladder, esophagus, gut, liver, lung, ovaries, prostate and skin.
Natural antibody immunity against NY-ESO-1 is often seen in cancer patients but is absent in healthy individuals. The natural antibody 12D7 is thought to be capable of initiating cellular immune responses, a disease fighting mechanism that is now widely mobilized to fight cancer through the use of check point inhibitors.
The target of the 12D7 antibody, NY-ESO-1, is commonly found in high-grade malignancies. The therapeutic use of 12D7 may therefore offer the potential to target these aggressive tumors in part by activating cellular immunity or antibody directed immune responses to the site of tumors. Anti-NY-ESO-1 antibody therapy may benefit from being combined with other therapies that reduce immune suppression. These combination therapies in particular offer hope that 12D7 could be a breakthrough approach to unleashing anti-cancer immunity against many forms of cancer.
About True Human
(TM) Therapeutic Antibodies
Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human(TM) proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
DATE 2019: eSilicon to present two papers on advanced floor planning techniques with the Polytechnic University of Catalonia21.3.2019 01:35:00 CET | Pressemelding
BARCELONA, Spain, March 20, 2019 (GLOBE NEWSWIRE) -- What: eSilicon, a leading provider of FinFET-class ASICs, market-specific IP platforms and advanced 2.5D packaging solutions, with the Polytechnic University of Catalonia, Barcelona, Spain are presenting two papers on advanced floor planning techniques at DATE 2019, Florence, Italy. Who: Alex Vidal-Obiols, Jordi Cortadella, Jordi Petit, Department of Computer Science, Universitat Politècnica de Catalunya. Marc Galceran-Oms, Ferran Martorell, eSilicon EMEA, Barcelona, Spain. RTL-Aware Dataflow-Driven Macro Placement This paper proposes a novel multi-level approach for macro placement of complex designs dominated by macro blocks, typically memories. Using the hierarchy tree, the netlist is divided into blocks containing macros and standard cells and their dataflow affinity is inferred considering the latency and flow width of their interaction. This information, known by the RTL designer, is often lost during physical synthesis. The la
More than 200 million Android users in Europe will soon be asked to choose their new favorite browser20.3.2019 18:41:00 CET | Pressemelding
OSLO, Norway, March 20, 2019 (GLOBE NEWSWIRE) -- Soon, more than 200 million Android users in Europe will be able to choose their favorite browser. In a blog post, Google has outlined that it will “...do more to ensure that Android phone owners know about the wide choice of browsers and search engines available to download to their phones. This will involve asking users of existing and new Android devices in Europe which browser and search apps they would like to use.” The announcement follows a July 2018 decision of the European Commission which prompted Google to change its licensing model for Google apps built for Android phones. “Competition is essential for making better products. When people get to make a choice between competing apps, they will be able to choose the best app for their use, and not just the app that is presented as the system default, “ said Krystian Kolondra, EVP Opera browsers, “We believe this step on Android can help Europeans more easily discover and choose
UPDATE - Eurotunnel entrusts the mid-life renovation of its Passenger Shuttles to Bombardier Transportation20.3.2019 12:53:00 CET | Pressemelding
BERLIN, March 20, 2019 (GLOBE NEWSWIRE) -- As part of the 2018-2026 mid-life programme, Eurotunnel signed a contract with Bombardier Transportation to renovate nine “PAX” Shuttles. Composed in total of 254 wagons, each 800-meter long shuttle is made up for passengers’ vehicles with passengers remaining in their vehicles during for the 35-minute Channel crossing. In the 25-year period since the opening of the Channel Tunnel, these Shuttles have each travelled an average of 300 round trips per month and have enabled over 236 million passengers to travel very comfortably between France and Great-Britain. The contract is valued at €150 million ($171 million) over a period of seven years. Deliveries of the newly refurbished Shuttles will start in mid-2022 and continue until mid-2026. Teams from Bombardier France and Belgium1 originally designed and built these unique vehicles in the 90’s and launched Bombardier’s activities in France. This year, the company celebrates 30 years since its est
Consumers Love Messaging for Customer Service But Hate its Experience Silo20.3.2019 11:30:00 CET | Pressemelding
YouGov survey of US and UK consumers reveals that lack of consistent omnichannel experience is the biggest hurdle to faster adoption of messaging for customer service SUNNYVALE, Calif. and NEWBURY, United Kingdom, March 20, 2019 (GLOBE NEWSWIRE) -- eGain (NASDAQ: EGAN), the leading provider of digital-first, omnichannel customer engagement hubs, today announced the findings based on a consumer survey of the use of messaging for customer service. The survey revealed that consumers love the convenience of messaging but struggle mightily with its experience silo. Conducted by YouGov on behalf of eGain, the survey was based on responses from 1777 consumers who messaged a business for customer service in the last 12 months. When asked about their struggles1 when messaging businesses for customer service: 43% hated repeating information across agents or when escalating to other channels; 28% struggled with the speed of response; and 23% were stumped by the relevance of response. Another inte
IMImobile announces availability of its enterprise communications platform IMIconnect on Salesforce AppExchange20.3.2019 09:00:00 CET | Pressemelding
IMIconnect’s AppExchange app enables Salesforce users to automate two-way customer interactions across 10+ communication channels LONDON, March 20, 2019 (GLOBE NEWSWIRE) -- IMImobile today announced the availability of its enterprise cloud communications platform IMIconnect on Salesforce AppExchange. This can enable businesses utilising the Salesforce Platform to rapidly launch and orchestrate two-way, trigger-based customer communications, across 10+ communication channels including SMS, WhatsApp, Apple Business Chat, In App and Push, amongst others. The IMIconnect for Salesforce App will augment the existing customer interaction capabilities of Salesforce Service Cloud, Sales Cloud, Commerce Cloud and Field Service Lightning to enable proactive customer engagement and reduce the cost of serving customers across touchpoints. Enterprises will be able to automate communications, such as order and delivery notifications for retailers, engineer appointment bookings for utility providers a
Eurotunnel entrusts the mid-life renovation of its Passenger Shuttles to Bombardier Transportation20.3.2019 08:30:00 CET | Pressemelding
BERLIN, March 20, 2019 (GLOBE NEWSWIRE) -- As part of the 2018-2026 mid-life programme, Eurotunnel is signing a contract with Bombardier Transportation to renovate nine “PAX” Shuttles. Composed in total of 254 wagons, each 800-meter long shuttle is made up for passengers’ vehicles with passengers remaining in their vehicles during for the 35-minute Channel crossing. In the 25-year period since the opening of the Channel Tunnel, these Shuttles have each travelled an average of 300 round trips per month and have enabled over 236 million passengers to travel very comfortably between France and Great-Britain. The contract is valued at €150 million ($171 million) over a period of 7 years. Deliveries of the newly refurbished Shuttles will start in mid-2022 and continue until mid-2026. Teams from Bombardier France and Belgium1 originally designed and built these unique vehicles in the 90’s and launched Bombardier’s activities in France. This year, the company celebrates 30 years since its est